Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Repurposing metformin for the prevention of cancer and cancer recurrence.

Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG.

Diabetologia. 2017 Sep;60(9):1639-1647. doi: 10.1007/s00125-017-4372-6. Epub 2017 Aug 3. Review.

PMID:
28776080
2.

Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank.

McCaskill-Stevens W, Pearson DC, Kramer BS, Ford LG, Lippman SM.

Cancer Prev Res (Phila). 2017 Feb;10(2):99-107. doi: 10.1158/1940-6207.CAPR-16-0230. Epub 2016 Dec 13. Review.

3.

Outcomes of Implementing an Evidence-Based Hypertension Clinical Guideline in an Academic Nurse Managed Health Center.

Dyal B, Whyte M, Blankenship SM, Ford LG.

Worldviews Evid Based Nurs. 2016 Feb;13(1):89-93. doi: 10.1111/wvn.12135. Epub 2016 Jan 13.

PMID:
26765990
4.

Predictive Value Tools as an Aid in Chemopreventive Agent Development.

Dunn BK, Steele VE, Fagerstrom RM, Topp CF, Ransohoff D, Cunningham C, Lubet R, Ford LG, Kramer BS.

J Natl Cancer Inst. 2015 Sep 28;107(12):djv259. doi: 10.1093/jnci/djv259. Print 2015 Dec.

5.

Prevention and early detection of prostate cancer.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A.

Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6. Review.

6.

Estimates of benefits and harms of prophylactic use of aspirin in the general population.

Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A.

Ann Oncol. 2015 Jan;26(1):47-57. doi: 10.1093/annonc/mdu225. Epub 2014 Aug 5. Review.

7.

Phase III prostate cancer chemoprevention trials.

Parnes HL, Brawley OW, Minasian LM, Ford LG.

Recent Results Cancer Res. 2014;202:73-7. doi: 10.1007/978-3-642-45195-9_9.

PMID:
24531780
8.

Long-term survival of participants in the prostate cancer prevention trial.

Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG.

N Engl J Med. 2013 Aug 15;369(7):603-10. doi: 10.1056/NEJMoa1215932.

9.

Exemestane for breast cancer prevention: a critical shift?

Decensi A, Dunn BK, Puntoni M, Gennari A, Ford LG.

Cancer Discov. 2012 Jan;2(1):25-40. doi: 10.1158/2159-8290.CD-11-0248. Review.

10.

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH.

JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.

11.

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S.

J Clin Oncol. 2011 Nov 1;29(31):4160-7. doi: 10.1200/JCO.2010.32.9615. Epub 2011 Sep 26.

12.

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).

Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, Vogel VG, Wolmark N.

Am J Obstet Gynecol. 2011 Dec;205(6):535.e1-5. doi: 10.1016/j.ajog.2011.06.067. Epub 2011 Jun 24.

13.

Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis.

Jordan VC, Ford LG.

Cancer Prev Res (Phila). 2011 May;4(5):633-7. doi: 10.1158/1940-6207.CAPR-11-0185. Epub 2011 Apr 10.

14.

A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Dunn BK, Richmond ES, Minasian LM, Ryan AM, Ford LG.

Nutr Cancer. 2010;62(7):896-918. doi: 10.1080/01635581.2010.509833. Review.

PMID:
20924966
15.

Breast cancer prevention trials: large and small trials.

Arun B, Dunn BK, Ford LG, Ryan A.

Semin Oncol. 2010 Aug;37(4):367-83. doi: 10.1053/j.seminoncol.2010.05.004. Review.

PMID:
20816507
16.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

17.

Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention.

Dunn BK, Ryan A, Ford LG.

Recent Results Cancer Res. 2009;181:183-93. Review.

PMID:
19213568
18.

The use of tamoxifen and raloxifene for the prevention of breast cancer.

Wickerham DL, Costantino JP, Vogel VG, Cronin WM, Cecchini RS, Ford LG, Wolmark N.

Recent Results Cancer Res. 2009;181:113-9. Review.

19.

Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.

Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, Coltman CA Jr, Thompson IM.

Cancer Prev Res (Phila). 2008 Aug;1(3):167-73. doi: 10.1158/1940-6207.CAPR-08-0078. Epub 2008 May 18.

20.

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr.

JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.

21.

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA Jr, Thompson IM.

J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83. Epub 2007 Sep 11.

PMID:
17848673
22.

Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.

Dunn BK, Ford LG.

Eur J Cancer Prev. 2007 Jun;16(3):232-42. Review.

PMID:
17415094
23.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP).

JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

PMID:
16754727
24.

The prostate cancer prevention trial: design, biases and interpretation of study results.

Goodman PJ, Thompson IM Jr, Tangen CM, Crowley JJ, Ford LG, Coltman CA Jr.

J Urol. 2006 Jun;175(6):2234-42.

PMID:
16697846
25.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

PMID:
16288118
26.

Estimated impact of the Prostate Cancer Prevention Trial on population mortality.

Unger JM, Thompson IM Jr, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA Jr.

Cancer. 2005 Apr 1;103(7):1375-80.

27.

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA Jr.

J Natl Cancer Inst. 2005 Jan 19;97(2):94-102.

PMID:
15657339
28.

Prevention of hormone-related cancers: prostate cancer.

Parnes HL, Thompson IM, Ford LG.

J Clin Oncol. 2005 Jan 10;23(2):368-77. Review.

PMID:
15637399
29.

Prevention of hormone-related cancers: breast cancer.

Dunn BK, Wickerham DL, Ford LG.

J Clin Oncol. 2005 Jan 10;23(2):357-67. Review.

PMID:
15637398
30.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr.

N Engl J Med. 2004 May 27;350(22):2239-46. Erratum in: N Engl J Med. 2004 Sep 30;351(14):1470.

31.

Implementation of the Prostate Cancer Prevention Trial (PCPT).

Goodman PJ, Tangen CM, Crowley JJ, Carlin SM, Ryan A, Coltman CA Jr, Ford LG, Thompson IM.

Control Clin Trials. 2004 Apr;25(2):203-22.

PMID:
15020037
32.

The influence of finasteride on the development of prostate cancer.

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr.

N Engl J Med. 2003 Jul 17;349(3):215-24. Epub 2003 Jun 24.

33.

Prevention and early detection clinical trials: opportunities for primary care providers and their patients.

Ford LG, Minasian LM, McCaskill-Stevens W, Pisano ED, Sullivan D, Smith RA.

CA Cancer J Clin. 2003 Mar-Apr;53(2):82-101.

34.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
35.

Breast cancer prevention: the next steps.

Dunn BK, McCaskill-Stevens W, Ford LG.

Eur J Cancer. 2000 Sep;36 Suppl 4:S53-4. No abstract available.

PMID:
11056319
36.
38.

Tamoxifen Breast Cancer Prevention Trial--an update.

Ford LG, Johnson KA.

Prog Clin Biol Res. 1997;396:271-82. No abstract available.

PMID:
9108604
39.

The community clinical oncology program: its effect on clinical practice.

Warnecke RB, Johnson TP, Kaluzny AD, Ford LG.

Jt Comm J Qual Improv. 1995 Jul;21(7):336-9. No abstract available.

PMID:
7581736
40.

Design of the Prostate Cancer Prevention Trial (PCPT).

Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr, Brawley OW, Ford LG.

Control Clin Trials. 1995 Jun;16(3):150-63.

PMID:
7540965
41.

Estrogen replacement therapy in breast cancer survivors.

Perlman JA, Johnson K, Nayfield S, Ford LG.

JAMA. 1995 Feb 22;273(8):619-20; author reply 621. No abstract available.

PMID:
7844867
42.

The potential for hormonal prevention trials.

Ford LG, Brawley OW, Perlman JA, Nayfield SG, Johnson KA, Kramer BS.

Cancer. 1994 Nov 1;74(9 Suppl):2726-33. Review.

PMID:
7954293
43.

5-Alpha-reductase inhibition and prostate cancer prevention.

Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS.

Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):177-82. Review.

44.

Overview of U.S. National Cancer Institute (USNCI) chemoprevention research.

Johnson KA, Ford LG, Kramer B, Greenwald P.

Acta Oncol. 1994;33(1):5-11. Review.

PMID:
8142125
45.

Vasectomy and increased risk of prostate cancer.

Perlman JA, Brawley OW, Ford LG, Kramer BS.

JAMA. 1993 Aug 11;270(6):706-7. No abstract available.

PMID:
8336364
46.

Re: Chemoprevention studies in the community clinical oncology program.

Johnson KA, Brawley OW, Perlman JA, Ford LG.

J Natl Cancer Inst. 1993 May 19;85(10):832-3. No abstract available.

PMID:
8487329
47.

Potential role of tamoxifen in prevention of breast cancer.

Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS.

J Natl Cancer Inst. 1991 Oct 16;83(20):1450-9. Review.

PMID:
1920492
48.

Early detection and control of cancer in clinical practice.

Bergner M, Allison CJ, Diehr P, Ford LG, Feigl P.

Arch Intern Med. 1990 Feb;150(2):431-6.

PMID:
2302018
49.

Results of a national survey of characteristics of hospital tumor conferences.

Henson DE, Frelick RW, Ford LG, Smart CR, Winchester D, Mettlin C, Yates JW.

Surg Gynecol Obstet. 1990 Jan;170(1):1-6.

PMID:
2294625
50.

Cancer control research for community programs: the National Cancer Institute initiative.

Hunter CP, Bavier AR, Ford LG.

Cancer Detect Prev. 1990;14(6):633-7.

PMID:
2257561

Supplemental Content

Support Center